Vasculitis- Pipeline Insight, 2022

DelveInsight’s, “Vasculitis- Pipeline Insight, 2022,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Vasculitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage
Vasculitis Understanding

Vasculitis: Overview
Vasculitis is a term for a group of rare diseases that cause inflammation of blood vessels. These vessels include arteries and veins. There are many types of vasculitis, and they may vary greatly in symptoms, severity and duration. Most types of vasculitis are rare, and the causes are generally not known. Vasculitis affects persons of both sexes and all ages. A few forms of vasculitis affect certain groups of people. For instance, Kawasaki disease occurs only in children. IgA Vasculitis is much more common in children than adults. On the other hand, giant cell arteritis occurs only in adults over 50-years-old. Vasculitis can result in poor blood flow to tissues throughout the body, such as the lungs, nerves and skin. The different types of vasculitis are classified according to the size and location of the blood vessels that are affected. When largest arteries, aorta and major branches: Giant cell arteritis, Takayasu’s arteritis, aortitis in Cogan’s syndrome, aortitis in spondylarthropathies, isolated aortitis. When medium size arteries are affected: Kawasaki disease, Polyarteritis nodosa. When Arteries and veins of various sizes: Beh?et’s disease and Relapsing polychondritis and many more. A result of vasculitis is that the tissues and organs supplied by affected blood vessels do not get enough blood. This can cause organ and tissue damage that can even lead to death. Vasculitis has a wide range of signs and symptoms (what you see and feel), such as: Shortness of breath and cough, Numbness or weakness in a hand or foot, Red spots on the skin (“purpura”), lumps (“nodules”) or sores (“ulcers”).On the other hand, vasculitis of the kidneys may produce no symptoms at first but is still a serious problem. Vasculitis can be mild or disabling, or even lead to death. Patients can have one episode of vasculitis or have repeated episodes over several years. Physicians suspect vasculitis when a patient has symptoms and abnormal results of the physical exam, lab tests or both, and there is no other clear cause. The most common tests are: Biopsy?surgical removal of a small piece of tissue for inspection under a microscope, angiography?a type of X-ray to look for abnormalities of blood vessels and Blood tests. For most patients, doctors can detect the type of vasculitis based on the size of the affected blood vessels (see Table) and the organs involved. To find small-vessel vasculitis, doctors most often do a biopsy, such as of the skin or a kidney. Detection of medium-vessel vasculitis happens by either biopsy (for instance, of skin, nerve or brain) or angiography. Angiography also is the test that often finds large-vessel vasculitis

"Vasculitis- Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vasculitis pipeline landscape is provided which includes the disease overview and Vasculitis treatment guidelines. The assessment part of the report embraces, in depth Vasculitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vasculitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Vasculitis R&D. The therapies under development are focused on novel approaches to treat/improve Vasculitis.

Vasculitis Emerging Drugs Chapters
This segment of the Vasculitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vasculitis Emerging Drugs
• Secukinumab :Novartis
Secukinumab inhibits interleukin (IL)-17A, and has shown significant benefits in conditions mediated by this cytokine such as plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. There also are experimental and preclinical data that point towards a role for IL-17A in the pathogenesis of giant cell arteritis, and therefore IL-17A inhibition by blocking vascular inflammation is potentially a new therapeutic target. Secukinumab showed promise as a steroid-sparing agent in giant cell arteritis. Currently the drug is in Phase 3 stage of evaluation for the treatment Giant Cell Arteritis (GCA) . Giant cell arteritis (GCA) is the most common form of vasculitis that occurs in adults.
• Belimumab (Benlysta): GlaxoSmithKline
Benlysta, a BLyS-specific inhibitor, is a human monoclonal antibody that binds to soluble BLyS. Benlysta does not bind B cells directly. By binding BLyS, Benlysta inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells. The drug is in phase 3 of clinical trials for the treatment of Anti-neutrophil cytoplasmic antibody-associated vasculitis.
• Vilobelimab : InflaRx
InflaRx’s lead drug candidate, vilobelimab, is a first-in-class monoclonal antibody targeting the complement activation product C5a and is currently in clinical development for several indications, including ANCA-Associated Vasculitis (AAV), a rare, life-threatening autoimmune disease. Based on the eminent role of C5a in the progression of inflammation in this life-threatening disease, InflaRx is currently conducting clinical testing in AAV.
• AMB 301: Ambulero
AMB-301 is a promising gene therapy candidate for enhancing blood vessel formation, restoring tissue integrity, and eliminating the need for amputation as a treatment. It is a first-in-class gene therapy vector encoding a cell adhesion molecule, E-selectin. More than a decade of research in animal models with vascular disease suggests that providing E-selectin to damaged blood vessels and surrounding tissue promotes therapeutic angiogenesis, supports robust tissue regeneration, and improved limb function.
Further product details are provided in the report??..

Vasculitis: Therapeutic Assessment
This segment of the report provides insights about the different Vasculitis drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Vasculitis
There are approx. 40+ key companies which are developing the therapies for Vasculitis. The companies which have their Vasculitis drug candidates in the most advanced stage, i.e. phase III include, Novartis.
• Phases
DelveInsight’s report covers around 40+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Vasculitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vasculitis: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vasculitis therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vasculitis drugs.

Vasculitis Report Insights
• Vasculitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Vasculitis Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Vasculitis drugs?
• How many Vasculitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vasculitis?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Vasculitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vasculitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Novartis
• AbbVie
• InflaRx
• Janssen Biotech
• Beijing Defengrei Biotechnology
• Ambulero
• Visterra
• ChemoCentryx
• GlaxoSmithKline
• Roche
• CytoDyn
• Toleranzia
• Citryll
• Levolta

Key Products
• Belimumab (Benlysta)
• Upadacitinib
• Vilobelimab (IFX-1)
• BDB 1
• AMB 301
• Guselkumab
• Secukinumab
?